Prasugrel, a third generation thienopyridine and potent platelet inhibitor

P. A. Gurbel, U. S. Tantry

Research output: Contribution to journalReview article

Abstract

Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.

Original languageEnglish (US)
Pages (from-to)324-336
Number of pages13
JournalCurrent Opinion in Investigational Drugs
Volume9
Issue number3
StatePublished - Mar 1 2008

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Prasugrel, a third generation thienopyridine and potent platelet inhibitor'. Together they form a unique fingerprint.

  • Cite this